In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2

Blood

Volumn 116, Issue 18, 2010, Pages 3635-3644

  Maes, Ken ^a   Nemeth, Elizabeta ^b   Roodman, G David ^c   Huston, Alissa ^c   Esteve, Flavia ^c   Freytes, Cesar ^d   Callander, Natalie ^e   Katodritou, Eirini ^f   Tussing Humphreys, Lisa ^g   Rivera, Seth ^b   Vanderkerken, Karin ^a   Lichtenstein, Alan ^h   Ganz, Tomas ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f THEAGENIO CANCER HOSPITAL   (Greece)

^g U S DEPARTMENT OF AGRICULTURE   (United States)

^h UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; LUCIFERASE; STAT3 PROTEIN;

ANEMIA; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION;

EID: 78149304850     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-274571     Document Type: Article

References (33)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-2972.
2. Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196-206. (Pubitemid 36896125)
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
4. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
5. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia. Med Hypotheses. 2006;66(2):352-354.
6. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14(11):3262-3267.
7. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
8. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276.
9. Rivera S, Gabayan V, Ganz T. In chronic inflammation, there exists an IL-6 independent pathway for the induction of hepcidin. Blood (ASH Annual Meeting Abstracts). 2004;104(11):Abstract 3205.
10. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292-4297.
11. Katodritou E, Verrou E, Hadjiaggelidou C, et al. Erythropoiesis- stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol. 2008;83(9):697-701.
12. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204-3209.
13. Truksa J, Lee P, Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood. 2009;113(3):688-695.
14. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353-358.
15. Truksa J, Lee P, Beutler E. The role of STAT, AP-1, E-box, and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters. Blood Cells Mol Dis. 2007;39(3):255-262. (Pubitemid 47484476)
16. Drach J, Kaufmann H, Urbauer E, Schreiber S, Ackermann J, Huber H. The biology of multiple myeloma. J Cancer Res Clin Oncol. 2000;126(8):441-447.
17. Seckinger A, Meissner T, Moreaux J, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009;28(44):3866-3879.
18. Grcevic D, Kusec R, Kovacic N, et al. Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leuk Res. 2010;34(6):742-751.
19. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
20. Groppe J, Greenwald J, Wiater E, et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature. 2002;420(6916):636-642.
21. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38(5):531-539.
22. Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A. 2006;103(27):10289-10293.
23. Verga Falzacappa MV, Casanovas G, Hentze MW, Muckenthaler MU. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med. 2008;86(5):531-540.
24. Casanovas G, Mleczko-Sanecka K, Altamura S, Hentze MW, Muckenthaler MU. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med. 2009;87(5):471-480.
25. Yamamoto T, Matsuda T, Muraguchi A, Miyazono K, Kawabata M. Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells. FEBS Lett. 2001;492(3):247-253.
26. Yanagisawa M, Nakashima K, Takizawa T, Ochiai W, Arakawa H, Taga T. Signaling cross-talk underlying synergistic induction of astrocyte differentiation by BMPs and IL-6 family of cytokines. FEBS Lett. 2001;489(2-3):139-143.
27. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 2008;111(10):5195-5204.
28. Musch A, Rabe C, Paik MD, et al. Altered expression of TGF-beta receptors in hepatocellular carcinoma - effects of a constitutively active TGF-beta type I receptor mutant. Digestion. 2005;71(2):78-91.
29. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933-1939. (Pubitemid 47036327)
30. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233-241.
31. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005;18(4):509-524.
32. Fukui N, Zhu Y, Maloney WJ, Clohisy J, Sandell LJ. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am. 2003;85-A(3 suppl):59-66. (Pubitemid 36951118)
33. Island ML, Jouanolle AM, Mosser A, et al. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE-related hemochromatosis. Haematologica. 2009;94(5):720-724.